drugset / Trial / NCT05405985
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors \[AI\] (test) versus dual-chamber syringes \[DCS\] (reference) under controlled conditions in healthy adult subjects.
Timeline
- Start
- 2022-08-11
- Primary completion
- 2022-11-11
- Completion
- 2022-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemolizumab | Monoclonal antibody | 60 mg | Subcutaneous |
Indications
No indication recorded.